Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Wisconsin: - Langlade Hospital and Cancer Center — Antigo, Wisconsin
- ThedaCare Regional Cancer Center — Appleton, Wisconsin
- Ascension Saint Elizabeth Hospital — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in Wisconsin: - Aspirus Cancer Care-Antigo-Volm Cancer Center — Antigo, Wisconsin
- ThedaCare Regional Cancer Center — Appleton, Wisconsin
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- ThedaCare Cancer Care - Berlin — Berlin, Wisconsin
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Wisconsin: - Duluth Clinic Ashland — Ashland, Wisconsin
- Bellin Memorial Hospital — Green Bay, Wisconsin
- Mercyhealth Hospital and Cancer Center - Janesville — Janesville, Wisconsin
- Cancer Center of Western Wisconsin — New Richmond, Wisconsin
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in Wisconsin: - ThedaCare Regional Cancer Center — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
- Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
- Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Wisconsin: - ThedaCare Regional Cancer Center — Appleton, Wisconsin
- Ascension St. Francis Reiman Cancer Center — Franklin, Wisconsin
- HSHS Saint Mary's Hospital Medical Center - Green Bay — Green Bay, Wisconsin
- University of Wisconsin — Madison, Wisconsin
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in Wisconsin: - SSM Health Dean Medical Group ( Site 0087) — Madison, Wisconsin
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in Wisconsin: - Sheboygan Cancer & Blood Specialists — Sheboygan, Wisconsin
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Sponsor: Volastra Therapeutics, Inc.
NCT ID: NCT05902988
Sites in Wisconsin: - Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 2 Recruiting Industry
A study to evaluate the efficacy and safety of triplet combination of inavolisib plus ribociclib and fulvestrant versus placebo plus ribociclib and fulvestrant in the first-line setting in participants with endocrine-therapy-resistant horm…
Sponsor: Hoffmann-La Roche
NCT ID: NCT07405801
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 2 Recruiting Academic/Other
This is an exploratory phase II interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for 4-12 weeks (+/- 2 weeks).
Sponsor: Medical College of Wisconsin
NCT ID: NCT06361940
Sites in Wisconsin: - Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is a…
Sponsor: Nammi Therapeutics Inc
NCT ID: NCT06582017
Sites in Wisconsin: - Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
EARLY Phase 1 Recruiting Academic/Other
Despite broad advancements in endocrine therapy for ERα+ breast cancer, resistance ultimately develops. A common driver of resistance are known ESR1 mutations that lead to constitutively active receptor signaling and transcriptional regula…
Sponsor: University of Wisconsin, Madison
NCT ID: NCT04174352
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
- Wisconsin Oncology Network (WONIX) sites — Madison, Wisconsin
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Wisconsin: - Aspirus Cancer Care-Antigo-Volm Cancer Center — Antigo, Wisconsin
- ThedaCare Regional Cancer Center — Appleton, Wisconsin
- ThedaCare Regional Medical Center - Appleton — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Wisconsin: - Aspirus Langlade Hospital — Antigo, Wisconsin
- ThedaCare Regional Cancer Center — Appleton, Wisconsin
- Ascension Saint Elizabeth Hospital — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- ThedaCare Cancer Care - Berlin — Berlin, Wisconsin
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Wisconsin: - Massive Bio SYNERGY-AI site — Milwaukee, Wisconsin
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Wisconsin: - Bellin Memorial Hospital — Green Bay, Wisconsin
Phase 4 Recruiting Industry
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor…
Sponsor: AstraZeneca
NCT ID: NCT07357597
Sites in Wisconsin: - Research Site — Waukesha, Wisconsin
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Wisconsin: - ThedaCare Regional Cancer Center — Appleton, Wisconsin
Phase 4 Recruiting Industry
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x…
Sponsor: Guerbet
NCT ID: NCT04373564
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 4 Recruiting Academic/Other
The goal of this clinical trial is to compare patient-centered outcomes when screening digital breast tomosynthesis (DBT) exams are interpreted with versus without a leading FDA-cleared artificial intelligence (AI) decision-support tool in…
Sponsor: Jonsson Comprehensive Cancer Center
NCT ID: NCT06934239
Sites in Wisconsin: - University of Wisconsin-Madison — Madison, Wisconsin
Phase 4 Recruiting Academic/Other
The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be init…
Sponsor: University of Wisconsin, Madison
NCT ID: NCT03096418
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Recruiting Academic/Other
This investigation is a prospective breast cancer screening study open to all individuals on hormone therapy. Using a mixed methods approach, the study will 1) gather prospective quantitative breast imaging data in conjunction with hormone…
Sponsor: Medical College of Wisconsin
NCT ID: NCT06383026
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
NA Recruiting Academic/Other
This single-arm study is designed to test the hypothesis that a six-month intermittent fasting (IF) intervention is feasible for patients to adhere to and improves health-related quality of life while subjects are on adjuvant endocrine the…
Sponsor: Medical College of Wisconsin
NCT ID: NCT06106477
Sites in Wisconsin: - Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin